| Name | Title | Contact Details |
|---|
Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered products that target the underlying causes of the world`s most prevalent eye diseases. The company`s surgical glaucoma product portfolio features the OMNI Surgical System, a dually indicated MIGS device that facilitates the performance of both ab interno trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm`s canal and collector channels) with a single device and single corneal incision. The company`s non-surgical dry eye product portfolio consists of the TearCare for ophthalmologists and optometrists. TearCare is a software-controlled, wearable, therapeutic eyelid technology designed to melt and clear obstructions of the meibomian glands within the eyelids. Leveraging the full functionality of the blinking eye, proprietary SmartLid™ technology is designed to conform to all eyelid anatomies and achieve therapeutic meibum melting temperatures at the tarsal conjunctiva thereby clearing meibomian gland obstructions while sparing the cornea. Improved meibum production results in a higher quality lipid layer and higher quality tears.
Unilife is a U.S-based medical device and technology company that designs, develops, manufactures and supplies innovative, differentiated delivery systems for injectable drugs, biologics and vaccines. Unilife has a broad portfolio of injectable drug delivery systems including prefilled syringes, auto-injectors, wearable injectors, drug reconstitution delivery systems, ocular delivery systems and novel devices. Unilife builds long-term partnerships with pharmaceutical and biotechnology companies seeking to leverage our products to enable, enhance and differentiate their injectable therapies. Unilife can develop or customize its device technologies to address the specific drug, commercial and patient needs of its pharmaceutical customers. Unilife’s dynamic business environment, advanced operational capabilities, world-class team and stringent quality processes enables the Company to serve the device innovation needs of its pharmaceutical customers with speed, agility and reliability. A state-of-the-art global headquarters and manufacturing facility in York, PA serves as an integrated center for the seamless design, development, production, quality control, regulatory compliance and commercial supply of its products.
Integrity Applications is dedicated to developing breakthrough innovations in non-invasive glucose monitoring devices. Since its founding in 2001, Integrity Applications has been committed to improving the quality of life for people with diabetes by removing the obstacles of traditional invasive devices, namely painful pricking of fingertips, added costs as a result of disposables, as well as inconvenience. Integrity Applications has developed a state-of-the-art way to measure glucose levels using three non-invasive technologies, ultrasound, thermal, and electromagnetic in combination with a proprietary algorithm to produce a weighted glucose measurement. After proof of concept in 2002, Integrity Applications developed the first working prototype, GlucoTrack in August 2003. GlucoTrack® Model DF-F received CE Mark approval in June 2013 and KFDA in March 2016. GlucoTrack is currently being marketed in the European Union and in South Korea.
Profound Medical is a Canadian medical device company that has developed a unique and minimally invasive procedure to ablate the prostate gland in prostate cancer patients.
Mortara Instrument Inc. is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.